Media ReleasesNoxopharm

View All Noxopharm News


NOXCOVID Trial Advances to Final Stage

• Positive review of hospitalized COVID-19 patients triggers approval to move from Part 1 to Part 2 of the trial
• Top dose of 1800 mg Veyonda daily to be used in final patient cohort
• Tests on blood cytokine levels in Part 1 patients underway

For more information, please download the attached PDF
Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.